Jump Financial LLC Sells 57,886 Shares of Moderna, Inc. (NASDAQ:MRNA)

Jump Financial LLC lowered its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 78.5% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 15,860 shares of the company's stock after selling 57,886 shares during the period. Jump Financial LLC's holdings in Moderna were worth $659,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Inspire Trust Co. N.A. increased its holdings in shares of Moderna by 73.5% during the third quarter. Inspire Trust Co. N.A. now owns 16,525 shares of the company's stock valued at $1,104,000 after acquiring an additional 7,000 shares in the last quarter. Principal Financial Group Inc. grew its position in Moderna by 4.2% during the 3rd quarter. Principal Financial Group Inc. now owns 379,451 shares of the company's stock valued at $25,359,000 after purchasing an additional 15,218 shares during the last quarter. GAMMA Investing LLC grew its position in Moderna by 31.9% during the 4th quarter. GAMMA Investing LLC now owns 3,173 shares of the company's stock valued at $132,000 after purchasing an additional 768 shares during the last quarter. Douglas Lane & Associates LLC grew its position in Moderna by 62.9% during the 4th quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company's stock valued at $32,175,000 after purchasing an additional 298,715 shares during the last quarter. Finally, Czech National Bank grew its position in Moderna by 6.6% during the 4th quarter. Czech National Bank now owns 73,424 shares of the company's stock valued at $3,053,000 after purchasing an additional 4,526 shares during the last quarter. Institutional investors own 75.33% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently commented on MRNA. Royal Bank of Canada reissued a "sector perform" rating and set a $40.00 price objective on shares of Moderna in a research report on Tuesday, February 18th. Bank of America cut their price objective on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research report on Tuesday, February 11th. Morgan Stanley dropped their price target on shares of Moderna from $39.00 to $32.00 and set an "equal weight" rating on the stock in a report on Wednesday, April 9th. Citigroup assumed coverage on shares of Moderna in a report on Thursday, March 13th. They set a "neutral" rating and a $40.00 price target on the stock. Finally, The Goldman Sachs Group downgraded shares of Moderna from a "buy" rating to a "neutral" rating and dropped their price target for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. Four equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $58.70.

Moderna Trading Up 0.9 %

NASDAQ MRNA traded up $0.24 on Monday, reaching $27.46. 5,752,053 shares of the stock were exchanged, compared to its average volume of 7,357,350. The firm has a market capitalization of $10.62 billion, a PE ratio of -2.96 and a beta of 2.23. Moderna, Inc. has a one year low of $23.15 and a one year high of $170.47. The company's 50-day simple moving average is $30.03 and its two-hundred day simple moving average is $38.15.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.